Global generics industry continues fight for equal footing with R and D sector at ICH
This article was originally published in SRA
Executive Summary
The global generics industry is continuing its fight to achieve parity with the research-based pharmaceutical industry at the International Conference on Harmonisation, protesting that it refuses to be relegated to the side lines in the key global drug development standards and guidelines initiative1.